Seeking Alpha


Send Message
View as an RSS Feed
View bio.bobby's Comments BY TICKER:
Latest  |  Highest rated
  • Galena: A Good Investment Gone Bad [View article]
    This is and has always been a scam.

    I hope Mark Ahn ends up in prison for this fraud.
    Mar 18 10:29 AM | 6 Likes Like |Link to Comment
  • Questcor Questions Pile Up Again [View article]
    The 'special sauce' ploy is disheartening and a cynical way to do business but, sadly, it also works in this context.

    Don't look to QCOR to develop Synacthen. I'll bet they drag their feet and never even submit an NDA.
    Mar 18 09:30 AM | Likes Like |Link to Comment
  • Questcor Questions Pile Up Again [View article]
    Problem is the release specification for Acthar is vassoporessin activity protein content. Citron could just as easily done this relevant test (it's described in exquisite detail in the USP), but choose not to.

    Also, what were the experimental conditions? This is critical in work like this, so why can't Citron release them? The story that they're trying to protect identity, and don't have a black marker to redact names, is absurd.
    Mar 17 08:21 AM | 1 Like Like |Link to Comment
  • Behind The Scenes With Dream Team, CytRx And Galena [View article]
    Really excellent work!

    Well done.
    Mar 13 10:21 AM | 7 Likes Like |Link to Comment
  • Targacept: Traveling The Rocky Road To Redemption [View article]
    OAB study will fail, would notion nicotinic receptor agonists will than dopamine is absurd. Only thing TRGT has done right is to scam AZN out of hundreds of millions.
    Mar 10 09:57 AM | Likes Like |Link to Comment
  • NanoViricides (NNVC) Acquisition In Review [View instapost]
    Mar 7 08:26 AM | 3 Likes Like |Link to Comment
  • How Will Subconscious Issues Influence FDA AdCom Voting On Afrezza? [View article]
    This is among the funniest things I have ever seen on SA.
    Mar 6 01:00 PM | 2 Likes Like |Link to Comment
  • Inovio Pharmaceuticals Raises $63 Million: Dr. J. Joseph Kim, CEO, Tells Us Why [View article]
    the only thing INO is good at is raising capital. Burned through $400 million over 31 years (founded in 1983!) with nothing to show for it---not a single drug approved. Impressive.
    Mar 5 05:22 PM | 2 Likes Like |Link to Comment
  • Auspex Is A Compelling Short Idea [View article]
    He was a great Aunt on my sister's side.
    Mar 5 01:20 PM | 3 Likes Like |Link to Comment
  • Celsion's OPTIMA Study: What You Need To Know [View article]
    "the post-hoc data that Celsion has pulled from the HEAT study would definitely suggest that the company does have a chance of finding success with this trial"

    LOL, just like the post hoc analysis of thermoscam prior to the heat study showed the heat study had a chance.

    Too funny!
    Feb 26 11:25 AM | 3 Likes Like |Link to Comment
  • Auspex Is A Compelling Short Idea [View article]
    Has no one realized that substituting deuterium for hydrogen and getting a longer half life is laughably obvious? Kinetic isotope effects have been known for decades: of course the deuterated form has a longer t1/2.... There's no chance these, or Concert's, patents will possibly hold up.
    Feb 21 05:29 PM | Likes Like |Link to Comment
  • Quiet Period Expiration For Auspex Pharmaceuticals Could Boost Stock Even Higher [View article]
    'The quiet period's expiration will likely lead to a temporary rise in the price of ASPX as the IPO underwriters distribute positive research reports on the rare disease biopharmaceutical firm"

    Really? How do you know they will be positive? Don't FINRA regulations, specifically reg. 2711, specifically prohibit forms from selling research like this?
    Feb 21 05:25 PM | Likes Like |Link to Comment
  • Celsion's Newest Cancer Treatment Adds To Upside [View article]
    Another great article, Sharon.

    Say, does CLSN pay for your stock promotion services?
    Feb 14 08:19 AM | 4 Likes Like |Link to Comment
  • Phase II Results Approaching For Prana's PBT2 In Alzheimer's Dementia And Huntington's Disease [View article]
    "As a conservative individual retail investor, we are not prone to hyperbole or Pollyannaish projections. That said, if PBT2 is successfully approved by regulators and produced and marketed globally, PRAN has the potentiality of becoming a $2 to $3 billion market cap. That means the shares could soar to a level of $100.00 per share or more, far above current trading levels of circa $5.00 per share. ...funfun"

    Do you understand that the second half of what you wrote contradicts the first?
    Feb 12 11:39 AM | 2 Likes Like |Link to Comment
  • Still Betting On DARA Bio [View article]
    "odd to see warrants priced below the offering"

    What does that tell you?
    Feb 12 11:25 AM | 1 Like Like |Link to Comment